Page last updated at 15:47 GMT, Tuesday, 17 February 2009

First case of haemophiliac vCJD

Section of brain for testing
CJD causes progressive damage to the brain

The Health Protection Agency has confirmed the first case of the human form of "mad cow disease" in a patient with haemophilia.

A post-mortem showed the man, who was "over 70" and had received plasma products before rules were introduced to limit contagion, died infected.

However he died of other causes and had not shown any symptoms, the HPA said.

Up to 4,000 haemophilia sufferers have been warned they could be at risk of variant Creutzfeldt-Jakob disease.

The HPA says it is still unclear how the man became infected with the prion protein that causes vCJD, but it is known that he was treated with several batches of UK blood plasma products before 1999, when the risk of transmission was not known.

Specifically, he was treated with a batch that was manufactured from the plasma of a donor who went on to develop symptoms of vCJD.

Risk confirmed

It is the first time that vCJD has been found in one of the thousands of haemophiliac patients who received blood plasma transfusions between 1980 and 2001. They have been told they all run a low risk of developing the disease.

This new finding may indicate that what was until now a theoretical risk may be an actual risk to certain individuals who have received blood plasma products
Professor Mike Catchpole
HPA

While this is the first case involving plasma products, three people have died after being infected with vCJD linked to blood transfusions.

"This new finding may indicate that what was until now a theoretical risk may be an actual risk to certain individuals who have received blood plasma products, although the risk could still be quite low," said Professor Mike Catchpole of the agency's Centre for Infections.

"We recognise that this finding will be of concern for persons with haemophilia who will be awaiting the completion of the ongoing investigations and their interpretation."

There is no test that can screen for vCJD, although development work is underway. However, even if an effective test were available, there is no means of treating the brain-wasting disease.

Professor Catchpole added: "This finding does not change our understanding of the risk from vCJD for other people in any specific way. But it does reinforce the importance of the precautionary measures that have been taken over the years."

UK plasma is no longer used for the production of the clotting treatment haemophiliacs require, and when suitable, synthetic products are used.

Chris James, the chief executive of the Haemophilia Society, said the Department of Health needed to now act "swiftly to give people the full details and offer them the appropriate support.

"Detailed information about recent developments must be made available immediately to all those who have been treated with potentially-infected plasma products."

David Allsop, professor of neuroscience at Lancaster University, said there was no need for widespread concern among haemophilia sufferers.

"The only real cause for concern is for other haemophilia patients who received clotting factors from the same infected human donor, at around the same period of time; and they can presumably be traced and given specialist advice."

VCJD was first detected in the mid-1990s but remains rare. The vast majority of the 164 deaths in the UK are believed to be linked to eating meat infected with bovine spongiform encephalopathy (BSE).



Print Sponsor


SEE ALSO
'New CJD type' discovered in US
10 Jul 08 |  Health
Hopes for better vCJD diagnosis
05 Jul 07 |  Health

RELATED INTERNET LINKS
The BBC is not responsible for the content of external internet sites


FEATURES, VIEWS, ANALYSIS
Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit

BBC navigation

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.

Americas Africa Europe Middle East South Asia Asia Pacific